Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
E-Mail Boston, Mass. -- Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the effi...
United States Dana Farber Cancer Institute Andrew Moore Chun Hau Chen Carol Ocallaghan Sabina Signoretti
Source: eurekalert.org